

Case Report

Not peer-reviewed version

---

# Lymphangi leiomyomatosis (LAM) with Tuberous Sclerosis Complex - A Case Study

---

[Aleksandra Marciniak](#)<sup>\*</sup>, [Jolanta Nawrocka-Rutkowska](#), [Agnieszka Brodowska](#), Andrzej Starczewski, [Iwona Szydłowska](#)

Posted Date: 30 September 2023

doi: 10.20944/preprints202309.2149.v1

Keywords: lymphangi leiomyomatosis; tuberous sclerosis complex; benign metastasizing leiomyomatosis



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Case Report*

# Lymphangi leiomyomatosis (LAM) with Tuberous Sclerosis Complex - A Case Study

Aleksandra Marciniak \*, Jolanta Nawrocka-Rutkowska, Agnieszka Brodowska, Andrzej Starczewski and Iwona Szydłowska

Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland, e-mail: o.marciniak@wp.pl\* (A.M.); jolanaw@poczta.onet.pl (J.N.-R.); agabrod@wp.pl (A.B.); andrzejstarcz@tlen.pl (A.S.); iwonaszyd@wp.pl (I.S.).

\* Correspondence: Correspondence: o.marciniak@wp.pl; Tel.: +48-91-425-0541

**Abstract:** Lymphangi leiomyomatosis (LAM) is characterized by lung cysts that cause lung deterioration, changes in the lymphatic system, and tumors in the kidneys. It mainly affects women of reproductive age and is a progressive disease. LAM can occur as an isolated disease or coexist with tuberous sclerosis (TSC). The source of LAM cells is unknown. Patients with confirmed LAM should be treated with an mTOR inhibitor, sirolimus, or everolimus. We present a case of LAM with TSC in a patient whose symptoms, including lymph nodes and chyloperitoneum, mainly concern the abdominal cavity.

**Keywords:** lymphangi leiomyomatosis; tuberous sclerosis complex; benign metastasizing leiomyomatosis

## 1. Introduction

Lymphangi leiomyomatosis (LAM) is characterized by lung cysts that cause lung deterioration, changes to the lymphatic system, and tumors in the kidneys. It mainly affects women of reproductive age and is a progressive disease [1,2]. LAM may occur as an isolated disease or coexist with tuberous sclerosis (TSC) [1,3]. Although LAM is not inherited, tuberous sclerosis is a hereditary condition and most women with TSC will develop LAM.

The essence of LAM is the presence of tumors in the lungs, which lead to a gradual loss of organ function. Tumors consist of abnormal muscle cells that enter the lungs through lymphatic vessels and whose source is unknown. During periods of high hormone concentrations, i.e., the reproductive period, lung function declines due to estrogen and progesterone receptors in LAM cells. In addition, estrogen stimulates cell proliferation and migration [1,4].

LAM cells carry inactivating mutations in the tumor suppressor genes TSC1 and TSC2. These proteins normally limit cell growth by suppressing the mammalian target of rapamycin complex 1. As previously mentioned, LAM can occur in two forms: hereditary (TSC-LAM) affects about 40% of patients with tuberous sclerosis (TSC) and sporadic (S-LAM) due to an acquired mutation, mainly in the TSC2 gene [5]. These are cases with no other TSC symptoms. TSC is a genetic disease of variable penetrance associated with many benign and rarely malignant tumors of the skin, eyes, brain, heart, lungs, liver, and kidneys. Mutations in the tumor suppressor genes TSC1 and TSC2 lead to aberrant signaling through the mTOR pathway and are found in both S-LAM and TSC-LAM. These pathways participate in regulating cellular functions including growth, motility, and survival [6]. LAM cells also express lymphangiogenic growth factors (vascular endothelial growth factor (VEGF)-C and VEGF-D), which facilitate the metastatic spread of LAM cells and the breakdown of the extracellular matrix by matrix metalloproteinases (MMPs), implicated in cyst formation [2,7].

In addition to pulmonary symptoms, LAM is also characterized by nodular lesions of the abdominal and pelvic lymph vessels, myometrial changes, and renal angiomyolipomas (AMLs) [2].

The source of LAM cells is unknown. They migrate to the lungs, forming cyst walls and nodular changes. Histologically, they are spindle-shaped cells with a large amount of eosinophilic cytoplasm. LAM cells also produce large amounts of matrix metalloproteinases (MMPs). They are responsible for tissue remodeling and extracellular matrix degradation, participating in tumor migration, invasion, and metastasis. Doxycycline is a drug that inhibits protease activity and has been shown to reduce lung degradation after 3 months of treatment [1,8].

The main clinical manifestations of LAM are dyspnea, pneumothorax (30% of patients), pleural effusion (10–30% of patients), mainly chylothorax; renal AML (30% of S-LAM patients and 80% of TSC-LAM patients), Lymphangi leiomyoma (16–38% of patients), and less frequently chyloperitoneum, chyluria, and chylopericardium [2,9,10]. The diagnostic method of choice is high-resolution computed tomography (HRCT) of the lungs. Seventy percent of LAM patients have shown elevated levels of VEGF-D, a growth factor that binds to VEGF receptor 3. Current guidelines recommend measuring serum VEGF-D in all patients with suspected LAM. In doubtful cases, a lung biopsy may be considered. In order to assess the pathology of the abdominal cavity, CT or magnetic resonance imaging is performed [2,10].

Patients with confirmed LAM should be treated with an mTOR inhibitor, sirolimus, or everolimus [2,11].

LAM occurs almost exclusively in women of reproductive age, and the presence of estrogen and progesterone receptors in LAM cells suggests that hormones influence the development and progression of the disease. Disease progression occurs during periods with high estrogen concentrations, e.g., during pregnancy or hormonal therapy, while the development of symptoms declines after menopause. Therefore, anti-estrogen therapy can help treat LAM. Estrogens regulate the presence of markers in LAM cells. One of them is a gp100 premelanosomal protein, called PMEL. It is recognized by the HMB-45 antibody used to diagnose LAM [1,7,11].

Reports on treatment with gestagens and estrogen receptor modulators are unclear and require further research.

A common feature of LAM and leiomyoma cells is abnormal proliferation and sensitivity to hormones (estrogens and progesterone), with the highest incidence in the reproductive period. Therefore, one hypothesis is that the source of LAM cells may be the uterus. In addition, a pathology in which myometrial cells migrate to the lungs and lymphatic vessels is benign metastasizing leiomyoma (BML) [1,2].

## 2. Case presentation

In June 2020, a 38-year-old patient was admitted to the Department of Gynecology, Endocrinology, and Gynecological Oncology of Pomeranian Medical University in Szczecin due to abdominal pain. During hospitalization, CT of the abdominal cavity was performed and the paraaortic lymph nodes were found to be enlarged up to 15 mm, and arranged in bundles. The right iliac lymph nodes were enlarged to 21 mm and the left- to 22 mm. Mesenteric lymph nodes were enlarged to 9 mm. In addition, in the kidneys, one of the foci had a 7 mm diameter of fat density, which implies AML.

The patient previously underwent two laparotomies with partial removal of the uterine fundus due to heavy menstrual bleeding: in 2009 and 2012. The obtained histopathological results revealed adenomyosis. In 2017, due to persistent vaginal bleeding, the patient underwent removal of the uterine corpus without an adnexa. In 2016, she underwent another laparotomy due to lymphoma suspicions. At that time, CT of the abdominal cavity revealed significantly enlarged lymph nodes. Histopathological examination diagnosed metastatic myoma. This examination revealed no atypia, necrosis, or mitotic activity. IHC: CD 34+, CD31+, SMA+, desmin+, and MIB-1+ in single cells.

The June 2020 hospitalization was prompted by a significant progression of the lymph nodes dimensions and suspicions of malignant transformation into sarcoma. Therefore, the patient qualified for laparoscopy iliac lymph node collection. The histopathological results confirmed a benign myomatosis diagnosis. The tumor's receptor status was also determined. Immunohistochemical staining revealed cells positive for estrogen and progesterone receptors (IHC: ER ++ in 60% cells, PR

+++ in 60% cells). A month after the operation, the patient was admitted to the hospital again due to a growing abdominal circumference and massive ascites. An abdominal ultrasound revealed ascites and a chest X-ray revealed a small amount of fluid in the pleural cavities. In laboratory tests, no deviations were found, apart from the reduced concentrations of total protein and albumin, and elevated concentrations of CAa125 and HE4 markers. An abdominal puncture was performed, and 1000 mL of fluid was collected for cytological assessment. The result was characteristic of exudate. The obtained fluid (lymph), accumulated in the abdominal cavity after lymph node extraction. Due to persistent ascites, with clinical symptoms (dyspnea and pain), ascites puncture was repeated after a month and again after 6 weeks of hospitalization, with 1500–2000 mL of fluid (lymph) obtained each time.

The patient's medical history indicates that she has epilepsy and was diagnosed with tuberous sclerosis—Bourneville's disease. The patient meets the diagnostic criteria for TSC, which includes – cutaneous manifestations- (hypopigmented macules on the skin of the trunk and limbs), neurological manifestations- (nodular lesions in the brain characteristic of TSC as described by MRI and epilepsy), and renal manifestations- (angiomyolipoma (AML). A genetic oncology clinic diagnosed the patient with tuberous sclerosis complex (TSC) based on clinical symptoms in 2021.

Due to the patient's BML (benign metastasizing leiomyomatosis) diagnosis with (+) ER and (+) PR and severe clinical symptoms (disease progression), we conducted a multidisciplinary analysis of this case with a rheumatologist and an oncologist. The medical council decided on a hormonal treatment with a long-acting GnRH analogues (aGnRH) and a selective estrogen receptor modulator—Tamoxifen. The patient's clinical condition improved as a result of our treatment.

In June 2021, the patient was admitted to the Department of Endocrinology due to the suspicions of a pancreatic neuroendocrine tumor. Based on laboratory tests, a pancreatic neuroendocrine tumor was excluded. A CT scan of the abdominal cavity and pelvis showed a progression in the size of the iliac and periaortic lymph nodes and an increase in the abdominal fluid. After multiple abdominal ascites punctures, we decided to persistently drain the peritoneal cavity, for one week, to avoid repeated punctures.

Chest CT revealed numerous disseminated, thin-walled cysts in the lungs, small nodules of various densities, and a 6 mm "milk glass" nodule. The picture was described as "non-specific".

The final LAM diagnosis was determined by the team and thoracic surgeons based on clinical condition analysis, and radiological (including HRCT) and pathomorphological examinations results. Treatment with mTOR inhibitors (everolimus or sirolimus) was recommended due to predominant abdominal symptoms. At the beginning, this therapy was combined with long-acting aGnRH and aromatase inhibitors. After clinically improving all symptoms, resolving ascites, and reducing lymph nodes size in the control CT examination, we decided to discontinue aGnRH therapy to avoid adverse side effects. The follow-up revealed no recurrence of symptoms and the patient's overall well-being for 14 months.

The recommended concentration of sirolimus in serum (5–15 ng/mL) was maintained at a dose of 1–2 mg per day. Letrozole was also administered at a dose of 2.5 mg per day. Additionally, the patient was treated for epilepsy with lamotrigine by a neurologist.

### 3. Discussion

The pathogenesis of LAM is unclear. LAM can be divided into sporadic and tuberous sclerosis-associated forms. Both forms of the disease can cause pulmonary symptoms. Extrapulmonary LAM has the same morphological features as pulmonary LAM and may occur concomitantly with or precede it [12].

Morphologic differential diagnoses include metastatic leiomyomas, metastatic leiomyosarcoma, gastrointestinal stromal tumor (GIST), malignant melanoma, and interstitial lung disease (sarcoidosis) [13]. Bourneville's disease is diagnosed based on genetic tests (mutations in the TSC1 or TSC2 genes) or by assessing clinical symptoms of the disease. The most important symptoms are skin angiofibromas, skin spots, multiple retinal hamartomas, cortical brain nodules, giant astrocytoma, heart rhabdomyosarcoma, lung lymphangioleiomyomatosis, and renal angioliopoma. In



addition, patients often have epilepsy and intellectual disabilities or behavioral disorders [14]. Pulmonary manifestations of TSC include lymphangioleiomyomatosis (LAM), which is seen in about 30–40% of reproductive-age women [1]. Our patient was diagnosed with tuberous sclerosis alongside epilepsy, a neurological manifestation, and angiomyolipoma in the kidneys. Instead of typical tumor locations within the lungs, our patient's tumors concerned only the lymph vessels in the abdominal cavity. This kind of myomatosis is what causes the main troublesome clinical symptoms. It is difficult to determine whether this is a separate symptom or a variant that may also contribute to tuberous sclerosis. Imaging examinations of the lungs showed non-specific changes.

Dysregulation of the mTOR signaling pathway is the main cause of abnormal LAM cell proliferation [15]. Microscopically detectable smooth muscle cell proliferation is the main cause of bronchiole obstruction and alveolar air blockage leading to spontaneous pneumothorax. In addition, blockage of the lymphatic vessels leads to chylothorax and chylic ascites [16–18]. Research into extrapulmonary LAM treatment has been limited. Since LAM occurs in approximately 30% of women with TSC alongside TSC1 and TSC2 tuberous sclerosis gene mutations, TSC genes play an important role in cell cycle regulation through the mammalian target rapamycin (mTOR) signaling pathway. Sirolimus, also called rapamycin (an mTOR inhibitor), blocks the mTOR signaling pathway and restores homeostasis in LAM cells [3,19]. Treatment with mTOR inhibitors brought significant improvement, primarily by resolving the chyloperitoneum. It also improved lung function and the quality of life for people with LAM. For this reason, after clinical trials, the Food and Drug Administration (FDA) announced its first-ever approval of sirolimus as a treatment for LAM in 2015 [20–23].

LAM cells express estrogen and progesterone receptors, and lung function declines when circulating estrogen levels are high. Many studies have shown that estrogen is an important factor in LAM cell proliferation, migration, and metastasis. Due to the co-expression of smooth muscle proteins (actin and desmin) and melanocyte markers (HMB-45, Melan-A, and MART-1), LAM cells are thought to derive from perivascular epithelial cells, although this is still unclear [1,8,11].

A pathology that should not be confused with lymphangioleiomyomatosis (LAM) is BML. Unlike BML, LAM causes atypical smooth muscle cell proliferation along blood vessels, lymph vessels, and small airways. HMB-45 immunohistochemical staining is positive for LAM but negative for BML [18].

Currently, assessing the concentrations of the lymphatic growth factors VEGF-C and VEGF-D helps in the diagnosis of LAM without requiring a lung biopsy. The fact that serum VEGF-D is elevated in 70% of LAM patients makes it a clinically useful diagnostic and prognostic biomarker. In addition, sirolimus, a drug that inhibits VEGF-D function and lymphocyte proliferation, stabilizes lung function and minimizes complications in LAM cases [10]. Recent research suggests a novel biomarker, FGF23 (a thirty-two-kDa protein secreted by osteocytes), to measure LAM activity. The authors assessed FGF23's association with pulmonary diffusion abnormalities in LAM patients [3].

This case suggests that personalized treatment strategies should be implemented for every patient with LAM. Differentiating LAM from BML is also important at the beginning of diagnosis. This study will be helpful in properly and effectively treating patients.

**Author Contributions:** Conceptualisation, A.M. and I.S.; methodology, A.M. and I.S.; data curation, A.M., J N-R., A.B. and I.S.; writing—original draft preparation, A.M and I.S.; writing—review and editing, A.M, I.S. A.S.; visualisation, A.M, I.S.; project administration, I.S; A.M.; A.S. All authors have read and agreed to the published version of the manuscript..

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Written informed consent has been obtained from the patient to publish this paper.

**Data Availability Statement:** The data presented in this study are available upon request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Prizant, H.; Hammes, S. Minireview: Lymphangioleiomyomatosis (LAM): The “Other” Steroid-Sensitive Cancer. *Endocrinology*. **2016**; *157*: 3374–3383.
2. McCarthy, C.; Gupta, N.; Johnson, S.R.; Yu, J.J.; McCormack, F.X. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. *Lancet Respir Med*. **2021**; *9*: 1313–1327.
3. Esposito, A.J.; Imani, J.; Shrestha, S.; Bagwe, S.; Lamattina, A.M.; Vivero, M.; Goldberg, H.J.; Rosas, I.O.; Henske, E.P.; El-Chemaly, S.Y. Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion. *J Bras Pneumol*. **2023**; *49*: e20220356. doi: 10.36416/1806-3756/e20220356.
4. Ağaçkiran, Y.; Ertürk, A.; Yeşiller, F.I.; Hoca, N.T.; Ustün, L.N.; Capan, N. Pulmonary lymphangioleiomyomatosis: a rare case. *Turk Patoloji Derg*. **2014**; *30*: 233–236.
5. Xu, K.; Xu, W.; Liu, S.; Yu, J.; Tian, X.; Yang, Y.; Wang, S.; Zhang, W.; Feng, R.; Zhang, T. Lymphangioleiomyomatosis. *Semin Respir Crit Care Med*. **2020**; *41*: 256–268.
6. Kundu, N.; Holz, M. Lymphangioleiomyomatosis: a metastatic lung disease. *Am J Physiol Cell Physiol*. **2023**; *324*: 320–326.
7. Nijmeh, J.; El-Chemaly, S.; Henske, E.P. Emerging biomarkers of lymphangioleiomyomatosis. *Expert Rev Respir Med*. **2018**; *12*: 95–102.
8. Cottin, V.; Archer, F.; Leroux, C.; Mornex, J.F.; Cordier, J.F. Milestones in lymphangioleiomyomatosis research. *Eur Respir Rev*. **2011**; *20*: 3–6.
9. McCormack, F.X. Lymphangioleiomyomatosis: a clinical update. *Chest*. **2008**; *133*: 507–16.
10. O'Mahony, A.; Lynn, E.; Murphy, D.; Fabre, A.; McCarthy, C. Lymphangioleiomyomatosis: a clinical review. *Breathe (Sheff)*. **2020**; *16*: 200007. doi: 10.1183/20734735.0007-2020
11. Gibbons, E.; Minor, B.; Hammes, S.R. Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet. *Endocr Relat Cancer*. **2023**; *30*: e230102. doi: 10.1530/ERC-23-0102.
12. Fu, W.; Li, Y.; Li, H.; Yang, P.; Xing, X. Solitary extrapulmonary lymphangioleiomyomatosis of the liver: A case report and literature review. *Exp Ther Med*. **2016**; *12*: 1499–1502. doi: 10.3892/etm.2016.3502.
13. Ofori, K.; Fernandes, H.; Cummings, M.; Colby, T.; Saqia, A. Benign metastasizing leiomyoma presenting with miliary pattern and fatal outcome: Case report with molecular analysis & review of the literature. *Respir Med Case Rep*. **2019**; *27*: 100831. doi: 10.1016/j.rmcr.2019.100831
14. Kingswood, J.; Bruzzi, P.; Curatolo, P.; de Vries, P.; Fladrowski, C. et al. TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. *Orphanet J Rare Dis*. **2014**; *9*: 182. doi: 10.1186/s13023-014-0182-9.
15. Chebib, N.; Archer, F.; Bobet-Erny, A.; Leroux, C.; Cottin, V. Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration. *Sci Rep*. **2018**; *8*: 14698. doi: 10.1038/s41598-018-32795-3.
16. Cong, C.V.; Tuan Anh, T.; Ly, T.; Duc, N. Pulmonary lymphangioleiomyomatosis (LAM): A literature overview and case report. *Radiol Case Rep*. **2022**; *17*: 1646–1655. doi:10.1016/j.radcr.2022.02.075. eCollection 2022 May.
17. Tümay, L.; Güner, O.; Zorluoğlu, A. An extrapulmonary manifestation of lymphangioleiomyomatosis: A rare case report. *Int J Surg Case Rep*. **2017**; *41*: 315–318. doi: 10.1016/j.ijscr.2017.10.057. Epub 2017 Nov 9.
18. Kołaczyk, K.; Chamier-Cienińska, K.; Walecka, A.; Chosia, M.; Szydłowska, I. et al. Pulmonary Benign Metastasizing Leiomyoma from the Uterine Leiomyoma: A Case Report. *Pol J Radiol*. **2015**; *80*: 107–110.
19. Moir, L.M. Lymphangioleiomyomatosis: Current understanding and potential treatments. *Pharmacol Ther*. **2016**; *158*: 114–24.
20. Wahid, S.; Chiang, P.C.; Luo, H.L.; Huang, S.C.; Tsai, E.M.; Chiang, P.H. Pelvic lymphangioleiomyomatosis treated successfully with everolimus: Two case reports with literature review. *Medicine (Baltimore)*. **2017**; *96*: e4562.
21. Sathirareuangchai, S.; Shimizu, D.; Vierkoetter, K.R. Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review. *Hawaii J Health Soc Welf*. **2020**; *79*: 224–229.
22. <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-s-rapamune-sirolimus-becomes-first-fda-approved-treatment-for-lymphangioleiomyomatosis-lam-a-rare-progressive-lung-disease>. Accessed August 07, 2023.
23. Song, X.; Cai, H.; Yang, C.; Xue, X.; Wang, J.; Mo, Y.; Zhu, M.; Zhu, G.; Ye, L.; Jin, M. Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment. *Front Med (Lausanne)*. **2020**; *7*: 554134. doi: 10.3389/fmed.2020.554134.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.